Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer

Trial Profile

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Ewing's sarcoma; Hodgkin's disease; Malignant melanoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 Jan 2018 According to a Bristol-Myers Squibb media release, the European Commission (EC) has expanded the indication of Yervoy (ipilimumab) to include treatment of advanced (unresectable or metastatic) melanoma in pediatric patients 12 years of age and older.
    • 03 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Jan 2012 Planned number of patients changed from 38 to 34 as reported by ClinicalTrials.gov (NCT01445379).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top